BIM
ASND icon

BlackRock Investment Management’s Ascendis Pharma A/S ASND Stock Holding History

BlackRock Investment Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-8,800
Closed -$153K – 4117
2015
Q1 		$153K Buy
+8,800
New +$160K ﹤0.01% 3255

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BlackRock Investment Management's ASND Position: Q2 2015 in Review

BlackRock Investment Management sold out of Ascendis Pharma A/S (ASND) in Q2 2015, closing a stake of 8,800 shares — an estimated $153K sold.

BlackRock Investment Management first reported a position in ASND in Q1 2015 and held it in 1 quarter. The position peaked at $153K in Q1 2015. 33 funds tracked by Wall St. Rank hold ASND as of Q2 2015.

  • BlackRock Investment Management reported no remaining Ascendis Pharma A/S position as of Q2 2015 after selling out during the quarter.
  • BlackRock Investment Management sold 8,800 Ascendis Pharma A/S shares in Q2 2015, an estimated $153K.
  • BlackRock Investment Management first reported a position in Ascendis Pharma A/S in Q1 2015 and held it in 1 quarter.
  • BlackRock Investment Management's Ascendis Pharma A/S position peaked at $153K in Q1 2015.
  • 33 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2015.

Based on BlackRock Investment Management's 13F filing for Q2 2015, filed 7 Aug 2015.